BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of an aggregate of 4,600,000 shares of common stock at a public offering price of $5.00 per share. The offering is expected to close on or about February 3, 2020, subject to customary closing conditions. Catabasis has granted the underwriters a 30-day option to purchase up to 690,000 additional shares of common stock at the public offering price, less the underwriting discount, to cover over-allotments, if any.
Oppenheimer & Co. Inc. is acting as sole underwriter for the offering.
The gross proceeds of the offering are expected to be approximately $23 million, prior to deducting the underwriting discount and other estimated offering expenses.
Catabasis intends to use the net proceeds from the offering for clinical trial and other research and development activities; initial commercialization preparations; and for working capital and other general corporate purposes.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy.

